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Objectives: Create trustworthy, rigorous, national clinical practice
guidelines for the practice of pediatric donation after circulatory
determination of death in Canada.
Methods: We followed a process of clinical practice guideline development based on World Health Organization and Canadian Medical
Association methods. This included application of Grading of Recommendations Assessment, Development, and Evaluation methodology. Questions requiring recommendations were generated based on
1) 2006 Canadian donation after circulatory determination of death
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guidelines (not pediatric specific), 2) a multidisciplinary symposium of
national and international pediatric donation after circulatory determination of death leaders, and 3) a scoping review of the pediatric donation after circulatory determination of death literature. Input from these
sources drove drafting of actionable questions and Good Practice
Statements, as defined by the Grading of Recommendations Assessment, Development, and Evaluation group. We performed additional
literature reviews for all actionable questions. Evidence was assessed
for quality using Grading of Recommendations Assessment, Development, and Evaluation and then formulated into evidence profiles that
informed recommendations through the evidence-to-decision framework. Recommendations were revised through consensus among
members of seven topic-specific working groups and finalized during
meetings of working group leads and the planning committee. External review was provided by pediatric, critical care, and critical care
nursing professional societies and patient partners.
Results: We generated 63 Good Practice Statements and seven
Grading of Recommendations Assessment, Development, and
Evaluation recommendations covering 1) ethics, consent, and
withdrawal of life-sustaining therapy, 2) eligibility, 3) withdrawal of
life-sustaining therapy practices, 4) ante and postmortem interventions, 5) death determination, 6) neonatal pediatric donation after
circulatory determination of death, 7) cardiac and innovative pediatric donation after circulatory determination of death, and 8) implementation. For brevity, 48 Good Practice Statement and truncated
justification are included in this summary report. The remaining
recommendations, detailed methodology, full Grading of Recommendations Assessment, Development, and Evaluation tables, and
expanded justifications are available in the full text report.
Conclusions: This process showed that rigorous, transparent clinical practice guideline development is possible in the domain of
pediatric deceased donation. Application of these recommendations will increase access to pediatric donation after circulatory
determination of death across Canada and may serve as a model
for future clinical practice guideline development in deceased
donation. (Pediatr Crit Care Med 2017; 18:1035–1046)
Key Words: clinical practice guidelines; deceased organ donation;
donation after circulatory determination of death; end-of-life care;
ethics

S

ince the publication of the 2006 consensus Canadian
recommendation (1), donation after circulatory determination of death (DCD) has become an increasingly
frequent path to donation for adults (2). Implementation of
pediatric DCD (pDCD) has lagged behind. According to 2014
data from Canadian Blood Services, DCD represented 21% of
total national deceased donation, but pDCD made up only 8%
of pediatric deceased donation. The purpose of this document
is to provide rigorously developed, evidence-based guidelines
that centers can use to develop pDCD in Canada.
One of the methods proposed by donation experts to
improve pDCD practice is standardization and evidence-based
recommendations (3). Current pDCD practice varies by jurisdiction and center (3, 4), likely as a result of the fact that no
November 2017 • Volume 18 • Number 11
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national or international guidelines specifically address pDCD.
As detailed below, we have employed a rigorous guideline
development methodology, including an extensive literature
review (5) and multidisciplinary consultation to create recommendations for all aspects of pDCD.

METHODS
The guideline was developed by a multidisciplinary guideline
development committee that included seven topic-specific
working groups (WGs). Two patient-family partners, professional society partners, and an international expert provided
external review. Funding was provided by Canadian Blood Services. No guideline development member disclosed any financial
conflicts of interest with for-profit entities, though several were
or are paid donor physicians associated with governmental notfor-profit organ donation organizations (ODOs), and others
have active research and academic activities in organ donation.
The guideline development committee adhered to a
rigorous development process based on the Grading of
Recommendations Assessment, Development, and Evaluation
(GRADE) methods and consistent with recommendations
from several national and international bodies (6–9). The
scope of the guideline included only controlled pDCD (e.g.,
after planned withdrawal of life-sustaining therapies [WLSTs]).
Specifically, we defined uncontrolled pDCD, or donation after
cardiac arrest outside of a WLST setting, to be outside the scope
of these guidelines. The guideline development committee and
WGs judged the quality of evidence and created evidence-todecision tables before making either “strong” or “conditional”
recommendations according to the GRADE approach (10).
In cases where the guideline development committee felt that
there was insufficient evidence or the balance of benefits and
harms was likely neutral, no recommendation was made.
In addition to GRADEd recommendations, the guideline
development committee formulated Good Practice Statements
(GPSs) in cases where there was a large body of indirect evidence strongly supporting the net benefit of the recommendation or there was no reasonable comparator (11). Full
consensus by all guideline development committee and WG
members was achieved for all recommendations.
This report is a summary that does not include all the recommendations or the justifications. For all recommendations,
justifications, complete GRADE tables for actionable recommendations, and a comprehensive description of the guideline
development process, please refer to the full report available at
http://www.organsandtissues.ca/s/english-expert/leading-practices-public-awareness-and-education. For a global review of the
pDCD literature, please refer to the associated scoping review (5).

2) The option of deceased donation, including pDCD, should
be routinely incorporated into end-of-life (EOL) care.
3) Healthcare systems should establish processes to ensure
pDCD access.
4) Throughout the WLST and donation process, healthcare
professionals must respect the dignity of the dying process.
5) The discussions and process of deceased donation should
respect the beliefs and values of the surrogate decision makers and other loved ones involved.
6) In recognition of diversity of perspectives on pDCD, healthcare professionals should be allowed to conscientiously
object to participation in pDCD.
		 a) In the case of healthcare professional objection, institutions should work to honor the surrogate decision makers’ wishes to donate.
Justification. The option to offer DCD as part of EOL care
is universally supported by professional societies and ODOs
that have examined the issue (1, 12–15), including two specific
endorsements from the American Academy of Pediatrics (16, 17).
Despite this broad consensus, some authors have expressed concerns around ethical aspects of pDCD (18, 19). Some individuals
within the healthcare team may have differing views on the meaning and permissibility of deceased organ and tissue donation
(OTD) based on societal, cultural, religious, and other personal
beliefs (20). These concerns justify the above recommendation to
allow conscientious objection by healthcare professionals to not
participate in pDCD, consistent with other policy and position
statements (12, 17, 21). However, considering the important role
donation can play in the lives of donor families, these objections
should not prohibit substitute decision makers and families from
participating in pDCD if they so desire, which is why we emphasize that institutions should work to accommodate these requests
using the principles of effective referral.
Decision-Making Process for WLST
Good Practice Statements.
7) The decision to pursue WLST must not be influenced
by donation potential and should proceed according to
accepted medical practices.
8) The ODO, organ recovery, and transplant team must not
be involved in the decision to pursue WLST or have direct
contact with surrogate decision makers before WLST decisions are finalized.
		

a) Treating teams may contact ODOs to assess eligibility prior
to the decision to pursue WLST, as long as there is no direct
contact between the ODO and surrogate decision makers.

RECOMMENDATIONS

9) The decision to pursue WLST should be made before
any discussion of OTD that is initiated by healthcare
professionals.

Ethics and WLST
Good Practice Statements.

		

1) pDCD is a medically and ethically viable pathway to provide access to deceased organ donation.
Pediatric Critical Care Medicine

b) If surrogate decision makers initiate organ donation discussions prior to the decision to pursue WLST, information may be provided, but consent discussions should be
deferred until WLST decisions have been finalized.
www.pccmjournal.org
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10) Safeguards should be in place to ensure that mitigation of
conflict of interest for the case where a patient who is a
potential donor and a patient who is a potential recipient
are being cared for in the same care unit.
Justification. In order to avoid real or perceived conflicts of
interest, decisions pertaining to OTD must be kept as separate
as possible from decisions regarding WLST. As is universally
supported in the literature, the above recommendations support that WLST decision-making follow established, best practices regardless of pDCD potential (12–14, 16, 17, 22–26).
One area we believe merits particular attention is when a
patient who is a potential donor and a patient who is a potential recipient are simultaneously cared for in the same unit. This
possibility is more likely in pediatric than adult practice given the
smaller number of recovery and transplant hospitals. We acknowledge this as a potential conflict and encourage systems to ensure
ethical safeguards if the substitute decision maker is motivated to
pursue donation in this setting. Measures to mitigate this potential conflict will depend on local context but could include ethics
consultation or a second opinion from an uninvolved clinician.
Eligibility
Good Practice Statements.
11) Individual transplant programs, in collaboration with
pediatric and neonatal healthcare professionals and
ODOs, should determine criteria for donor eligibility, limits of warm, and cold ischemic time. Special consideration
should be given for neonatal patients who are potential
donors.
12) Coroners must be notified prior to donation proceedings
according to provincial laws. If coroner evaluation and
approval to pursue pDCD is required, this should be done
prior to consent discussions with the surrogate decision
makers.
Justification. We chose to limit our recommendations related
to pDCD eligibility. Further national recommendations will
require input from multidisciplinary groups, including transplant surgeons and physicians caring for recipients of pDCD
organs, in order to form organ-specific recommendations. Current recommendations from groups such as the Canadian Society of Transplantation should inform these discussions, including
those on high-risk donors (27). These criteria will be subject to
change based on center experience, further research, and recommendations from organ-specific transplantation groups.

14)	The person or team discussing consent should have extensive knowledge of the local process and should clearly
identify their institutional affiliations.
15)	
Consent conversations with surrogate decision makers
should include the opportunity to discuss beliefs and values around all aspects of pDCD, including death and death
determination.
16)	At minimum, the following information should be provided to surrogate decision makers regarding the pDCD
process:
a) Logistics of the process, including that WLST may be
delayed due to pDCD logistics, and where WLST will
occur,
b) The procedures and methods of determining death,
including that these practices conform to accepted
medical and legal standards,
c) Which organs are potentially eligible for recovery,
d) That consenting for pDCD does not guarantee organ
recovery or transplantation,
e) If organ recovery is not possible, tissue donation may
remain an option,
f) How EOL care would proceed if they decline organ
donation or if recovery does not occur after attempted
donation,
g) That the treating team has no influence over allocation, which may include allocation to adult or pediatric
recipients,
h) That surrogate decision makers will be supported if
they consent to or decline pDCD, and
i) That consent can be withdrawn at any time, including
after the determination of death.
17)	Tests and interventions prior to death (antemortem interventions) to facilitate donation in pDCD require specific
and informed consent from the surrogate decision makers
for each intervention.
a) Antemortem interventions should only be undertaken
with disclosure and consideration of risks and benefits
to the patient who is a potential donor.
b) Antemortem interventions should not be intended to
hasten death.
c) Antemortem interventions should pose no more risk
to the patient than routine intensive care practices.

13)	Consent discussions for pDCD can include members of
the care team, representatives of the ODO, or healthcare
professionals from both groups.

18)	Antemortem interventions should be recognized as providing nonmedical benefit to the patient who is a potential donor by allowing realization of interest and intent to
donate despite the fact that these interventions provide no
medical benefit to the patient who is a potential donor.
This justifies surrogate decision maker’s authority to consent to interventions that pose no increased risk beyond
routine intensive care practices despite no medical benefit
to the patient who is a potential donor.

a) As stated in GPS 9 above, all discussions of organ donation initiated by healthcare providers must be deferred
until after WLST decisions are finalized.

Justification. How best to engage in consent discussions
was carefully considered for these recommendations. There
is significant practice variability concerning which healthcare

Consent for pDCD
Good Practice Statements.

1038
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professionals should be present during consent discussions.
Regardless of whether an ODO representative is present during
the consent request, we recommend that person have detailed
knowledge of the local processes and procedures. Further discussion of training requirements for people requesting consent
can be found under Actionable Recommendation 1. Furthermore, the stage in the EOL pathway at which ODOs are to be
notified varies across jurisdictions, often related to requirements of mandatory reporting laws. The laws and local practices of reporting of a patient who is a potential donor should
be carefully considered when establishing a pDCD protocol.
The understanding of consent for pDCD also requires an
understanding of the distinction between consent for interventions before (ante) and after (post) mortem. It is outside the
scope of these guidelines to extensively review the legal framework governing pDCD consent, but deceased donation in
Canada is governed by provincial tissue gift legislation. Similar
to the concept of “authorization” used more commonly in the
United States, permission to proceed with donation under gift
acts is different from, and legally less demanding than informed
consent for treatment of a living patient (28). Consideration of
benefit or harm posed to the patient, which forms the basis
of informed consent to treatment, cannot be applied in the
context of postmortem organ recovery any more than it can
applied to the processes of cremation or embalming (28).
pDCD, however, includes both authorization for postmortem organ recovery and consent for antemortem interventions
that do require full informed consent. A question that is often
raised in pDCD considerations is if substitute decision makers
or families can give valid consent for a procedure that might
cause harm or discomfort to the donor while providing medical benefit only to the organ recipient. Several authors (22, 29,
30), including the 2013 American shared position statement
from the American Thoracic Society, the Society for Heart and
Lung Transplantation, the Society of Critical Care Medicine,
the Association of Organ Procurement Organizations, and the
United Network of Organ Sharing (12), answer in the affirmative. Their rationale is that if the process presents potential risk
of harm that is similar to routine intensive care practices, and
the procedure is in line with parental values, an assumption of
altruism is legitimate (22, 29). The benefit to the patient who is
a potential donor is therefore allowing donation to proceed in
order to fulfill family or surrogate desire to donate, and it is this
benefit that justifies assumption of risk without direct medical
benefit. This is consistent with the ethical reasoning supporting children’s participation in medical research where there is
no hope for direct benefit to them. Furthermore, not allowing
patients’ substitute decision makers or families to accept this level
of risk in order to act altruistically in this circumstance would
limit their autonomy (21). These arguments, however, are not
universally accepted, and others claim that altruism on the part
of an incompetent child cannot be assumed based on parental
values (18). We conclude that divergent opinions regarding the
ethical acceptability of such antemortem interventions would be
a justifiable reason for healthcare professionals to excuse themselves from pDCD proceedings through conscientious objection.
Pediatric Critical Care Medicine

It is impossible to specifically recommend how to weigh
these risks and benefits in all the nuanced situations that will
arise for individual patients (e.g., heparin administration to a
patient with a remote history of an intracranial hemorrhage).
It is the responsibility of the treating team, with appropriate
ethical oversight, to ensure that protection of the interests of
the patient who is a potential donor remains the primary concern throughout these situations.
Any test of organ eligibility or those specific for allocation
(e.g., human leukocyte antigen matching) should be considered an antemortem test and should not be performed until
consent for the pDCD process and required investigations has
been obtained.
For further information regarding general best practices in
organ donation consent, please consult the recent report from
Canadian Blood Services (31).
Actionable Recommendation. “Should trained professionals versus professionals without specific training be used for
approaching families for consent in the setting of pediatric
donation after circulatory death?”
19) The panel did not make a recommendation regarding
minimal required training of professionals approaching
families for consent in the setting of pediatric donation
after circulatory death.
Justification. Although several observational reports
(32–43) suggest that trained requesting is effective at
increasing consent rates, the only randomized controlled
trial (44) showed no effect of involving trained ODO staff
at the time of consent. None of these studies were exclusive
to pediatrics or even DCD. Only one (33) of 13 references
examined family satisfaction after the consent process as
an outcome.
Considering the lack of conclusive evidence supporting
benefit, and the substantial system investment that would be
required to have trained requesters present at every consent
conversation, we chose to not recommend for or against this
intervention. For further information on effective requesting
techniques in deceased donation, please refer to the recently
published report from Canadian Blood Services (31).
Procedures for WLST in the Context of pDCD
Good Practice Statements.
20) WLST practice should be based on established ICU or
hospital practices, policies, and guidelines.
21) The critical care team must be responsible for patient
management between the decision to WLST and the determination of death.
22)	The ODO, organ recovery, and transplant team must not
be involved in any aspect of management of the dying
process.
23) WLST may occur in the critical care unit, near the operating room, or in the operating room, as determined by surrogate decision makers’ preferences, institutional logistics,
resources, and facilities.
www.pccmjournal.org
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24) Psychosocial, spiritual, and bereavement support should
be provided to surrogate decision makers regardless of
WLST location.
25) Wherever WLST occurs, surrogate decision makers and
other loved ones should be given the option to be physically present with the patient who is a potential donor
until the determination of death is complete.
26) The organ recovery team should not be physically present in the room until the determination of death has been
completed and the surrogate decision makers are escorted
from the bedside.
27) If a patient who is a potential donor is hospitalized where
pDCD is not available, and the surrogate decision makers
are motivated to donate, consideration should be given for
patient transfer to a hospital that performs pDCD.
Justification. The fiduciary responsibilities of ICU clinicians are first and foremost to act in the best interest of his
or her patient (12, 13, 16), and we therefore strongly support
that in the event of a conflict in management goals between
organ donation and optimal EOL care, care for the dying child
should always take precedence. As universally supported in
the published literature, WLST practices should be provided
with minimal deviations from standard practice, including
full support available for families (12–14, 16, 17, 21, 22, 25, 26,
45). Our group did not specifically deliberate on the issue of
whether the practice of surgical preparation of the patient who
is a potential donor (sterilization of the surgical field, draping, etc.) represented acceptable contact between the recovery team and the donor prior to death determination. In line
with other recommendations, if this practice is required by the
recovery team, it should be treated as an antemortem intervention requiring specific informed consent, and the recovery
team should in no way otherwise influence EOL care. Also if
practiced, this contact should not alter the recommendation
that the recovery team not be physically present in the room
at the time of death determination, and they should leave the
operating room after surgical preparation is completed and
before the parents enter.
Time From WLST to Determination of Death
Good Practice Statements.
28) A maximum time limit from the start of WLST to death,
beyond which organs will not be recovered, should be
established in collaboration with ODOs and local transplant teams.
Justification. The duration of acceptable warm ischemic
time (WIT) should be locally informed and based on organspecific concerns (13, 46, 47). Current practice in most pDCD
centers recommends WIT of 30–90 minutes, depending on the
organ to be recovered. Adult practices may vary from 1 to 4
hours depending on multiple factors, including limitations of
access to operating rooms. Our guideline committee did not
consist of transplant surgeons or posttransplantation physicians who could provide meaningful expertise into the effects
1040
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of various WIT thresholds on specific organs, and we therefore
specifically chose not to make recommendations regarding the
length of acceptable WIT.
Actionable Recommendation. “Should formal predictive
tools versus no formal tool (clinical judgment) be used for
predicting time of death within 30 or 60 minutes of WLST?”
29) The panel did not make a recommendation regarding use
of tools to predict the time from WLST to death.
Justification. Though a prediction tool developed by Shore
et al (48) has shown reasonable predictive value, it remains
to be tested against clinical judgment or prospectively validated. Prediction tools cause no direct harm to a patient, may
provide important information to the clinical team and surrogate decision makers, and are low cost. The risk, however,
is if clinicians choose whether or not to pursue donation proceedings based solely on such a tool without understanding
its strengths and limitations. Although future iterations may
result in improved sensitivity and specificity, we currently do
not recommend for or against the use of death prediction
tools.
Minimum Standards Required for Death
Determination in pDCD
Definition of Death Used for these Recommendations.
There is currently no Canadian federal, provincial, or territorial statute mandating how clinicians determine when a patient
is dead. As there is also no widely accepted medical standard
from Canadian professional societies, we have chosen, for
the purposes of this guideline, to use the following definition
taken from recently proposed guidelines at the World Health
Organization:
The definition of death by circulatory determination: The
permanent loss of capacity for consciousness and all brainstem
functions, as a consequence of permanent cessation of circulation.
Permanence is defined as loss of function that will not resume
spontaneously and will not be restored through intervention (49).
This definition is consistent both with current accepted
Canadian medical practice and the definitions used in the current clinical practice recommendations governing donation
circulatory death in adults (1).
Good Practice Statements. The following includes a summary of current Canadian laws and practices governing
deceased donation. These laws and recommendations should
be understood to represent the minimum standards necessary
to determine death. They do not preclude additional standards,
as long as those standards are accepted prior to implementation by all stakeholders.
30) The dead donor rule must be respected within the context
of pDCD.
31) Death must be determined by two physicians in accordance with accepted medical practice.
		

a) The two physicians must confirm their determinations
concurrently at the end of a hands-off period of observation during circulatory arrest.
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32) No physician who has active involvement in transplant
procedures or allocation of donated organs shall take any
part in donor death determination.
33) The minimum level of physician qualification required to
determine death in pDCD is as follows:
		

		

		

a) They possess the requisite skills and training. A particular level of specialty certification is not required, but
skills and training should include ability to interpret
monitoring used.
b) At least one of these physicians must be an attending
physician staff in the ICU of the patient and possess
full and current licensure for independent medical
practice in the relevant Canadian jurisdiction.
c) The second physician could be on an educational register (e.g., residents, fellows), as long as they have the
requisite skills and training.

34) The following criteria must be met before organ recovery:
		

		

		

a) Circulatory arrest, defined as the absence of anterograde arterial circulation. See actionable recommendations 37 and 38 for the specifics of how to determine
that absence.
b) A hands-off period of continuous observation of circulatory arrest during which no interventions are
undertaken to facilitate donation. See recommendation below for duration of hands-off period.
c) At the end of this period, death is legally determined,
and organ recovery may commence.

35) Recovery and transplantation of the heart in pDCD is consistent with the dead donor rule, as death is based on the
permanent cessation of circulation.
36) The same criteria should apply to all potential pDCD
donors including those undergoing withdrawal of
mechanical circulatory support such as extracorporeal
mechanical oxygenation (ECMO).
Justification. The definition of death used for these guidelines represents both current accepted Canadian practice and
is consistent with evolving international consensus (49). The
details of how cessation of circulation is determined and for
how long are detailed below in actionable recommendations 37
and 38. pDCD, practiced according to these practices and definitions, respects the dead donor rule, defined as “vital organs
should only be taken from dead patients and, correlatively, living patients must not be killed by organ retrieval” (50).
We have chosen to recommend that although the first physician determining death in pDCD must have a full, unrestricted license to practice, the second may be a trainee on an
educational register. This recommendation considers that the
death determination in pDCD requires skills or training that
would be readily available to a resident or fellow undergoing
training in a PICU or neonatal ICU (NICU). If the second
physician is on an educational register, he or she should be
reminded that they are not obligated to participate and that
a decision to participate or no will not affect their evaluation. Also, the second physician need not be from a certain
Pediatric Critical Care Medicine

specialty, as long as he or she possesses the capacity to determine death in this setting, specifically the ability to interpret
an arterial catheter waveform tracing.
In GPS 32, active involvement in transplant procedures or
allocation is defined as any involvement in postmortem surgical recovery procedures, discussions of which patient on the
transplant wait list will receive the donated organs, or participation in any part of the transplantation procedure (including
anesthesia of the recipient). Consultant physicians who might
be involved in evaluating the patient for donor eligibility and
might also care for a potential recipient (e.g., nephrologists)
would be excluded from participating in the determination of
death. As addressed in GPS 10, it is possible that intensive care
physicians will be involved directly or indirectly with the care of
both donor patients and those who receive transplanted organs
from the same donor due to the limited number of PICUs in
Canada. Ethical safeguards should be developed in these cases.
Regarding GPS 36, in the past, when DCD was more commonly referred to as “donation after cardiac death,” authors
argued that determining death by irreversible loss of cardiac
function precluded DCD cardiac transplantation (51, 52).
However, our guidelines specifically define death as permanent
loss of circulation in the donor. Whether the heart remains
unresuscitated in the donor or is removed and resuscitated in
another patient does not alter donor outcome: body and brain
circulation remains permanently ceased in the dead donor (53).
Thus, cardiac pDCD practiced according to these guidelines
would respect the dead donor rule.
Actionable Recommendation. “Should arterial line versus
palpable pulses and auscultation be used for confirmation of
lack of anterograde circulation?”
37) We recommend that a well-functioning arterial catheter be
used to confirm arrest of anterograde arterial circulation
for the determination of death. (strong recommendation,
low certainty in evidence)
Justification. Although not specific to a pDCD setting, data
from studies designed to test clinicians ability to determine
between low and nonpulsatile states suggest that even experienced PICU physicians commit errors (54–56). The panel
strongly felt that palpation of pulse was an inadequate method
to confirm lack of circulation. Arterial catheter monitoring is
commonly used, easily interpreted, and objective. The recommendation to rely on arterial catheter monitoring assumes a
functioning and verified arterial catheter. No other confirmation of loss of anterograde circulation (e.g., electrical asystole)
is necessary when a well-functioning arterial catheter is in
place. Although auscultation or palpation should not be used
to confirm lack of circulation, they could be applied to verify
that an observed flat waveform corresponds with the clinical
state. We make no recommendation as to the required site of
the arterial catheter.
Please see the full report for consideration of situations
when an arterial catheter is not possible for technical reasons
or due to surrogate decision maker refusal, including the use of
other modalities such as echocardiography.
www.pccmjournal.org
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Actionable Recommendation. “Should 10 minutes handsoff time versus 5 minutes hands-off time be used for death
determination in pDCD donors?”
38) We suggest 5 minutes of hands-off observation of arrest of
circulation prior to determination of death. (conditional
recommendation, very low certainty in evidence)
Justification. Currently, all Canadian adult and pediatric centers performing DCD use 5-minute hands-off period.
During this 5-minute period, also sometimes referred to as a
“no touch” period, no healthcare professional should have any
physical contact with the patient, and the physicians determining death should be constantly observing the method used to
confirm absent circulation. The period of time commences
when no visible pulsatility is observable on a well-functioning arterial catheter waveform or after the last evidence of
anterograde circulation (e.g., last opening of the aortic valve
by echocardiography). If evidence of circulation is detected
during the 5-minute hands-off period, the observation period
should recommence until 5 full minutes of absent circulation
are observed. This period is longer than any reported case of
autoresuscitation after WLST (57, 58), and organs transplanted
after this ischemic time have acceptable outcomes (59–61).
However, based on the low quality of the reviewed autoresuscitation evidence and the fact that no reports compared organ
outcomes using 5- versus 10-minute hands-off times, we chose
to make a conditional recommendation.
Ante and Postmortem Interventions
Good Practice Statements.
Antemortem.
39) Any intervention or test that may pose discomfort to the
patient who is a potential donor should be managed with
analgesia and/or sedation as per standard ICU practices.
40) Consideration should be given to the timing of administration of any antemortem pharmacologic intervention in
order to minimize any potential risks.
Postmortem.
41) Interventions that do or may reinstitute oxygenated brain
blood flow after death must not be performed, including
cyclic ventilation after reintubation for lung donation.
42)	Only the organ recovery team may carry out postmortem
surgical interventions.
Justification. The above recommendations emphasize that
any antemortem intervention, including transfer of a patient
who is a potential donor, carries the same requirements for
informed consent, minimization of risk, and respect for the
comfort of the patient as in routine care of ICU patients. Refer
to the “Consent for Antemortem Interventions” section above
for additional discussion.
Regarding postmortem interventions, our primary concern
was the need to avoid interventions that might reestablish oxygenated brain blood flow. Absence of oxygenated brain blood
flow is the key component of the determination of death, so
1042
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procedures that potentially reestablish that flow could violate
the dead donor rule. Understanding that risk, we recommend
that tracheal reintubation is permissible as long as cyclic ventilation is not provided. Through cardiopulmonary interactions,
cyclic ventilation has the theoretical risk of restoring oxygenation and brain circulation, and its avoidance has been recommended by other groups (12, 14).
Actionable Recommendation. “Should Heparin versus
no anticoagulation be used for pDCD as an ante mortem
intervention?”
43) The panel did not make a recommendation regarding
the universal administration of heparin in the setting of
pDCD.
Justification. Given the lack of available evidence for benefit
in pediatric or adult patients (62, 63) and concerns regarding any antemortem interventions that could cause harm to a
patient who is a potential donor, we make no recommendation
regarding routine antemortem heparin administration pDCD.
If given, practices such as dose and timing of administration
should be determined jointly by intensive care teams, ODOs,
and transplant programs to ensure that harm to a patient who
is a potential donor is minimized.
Actionable Recommendation. “Should regional oxygenated
perfusion techniques versus no such techniques be used for
improving organ outcome in controlled pDCD?”
44)	We recommend that regional perfusion not be used in the
setting of pDCD (strong recommendation, very low certainty in evidence).
Justification. Although not practiced in Canada, other jurisdictions have employed perfusion techniques (e.g., modified
ECMO) that provide oxygenated blood flow to abdominal
organs after death but prior to organ recovery, while excluding
blood brain flow. Reports of this practice were considered indirect to our question, since they were almost exclusive to adult
donors (64–74), and often involved antemortem interventions
such as cannulation that would be in conflict with current
Canadian pDCD practice.
Given the low quality of the evidence reporting benefit,
risk of the significant consequence of reestablishing brain
blood flow through inadequate aortic occlusion, and the cost/
resources involved, we feel that regional perfusion techniques
should not be used for pDCD (64, 73).
Although we do not recommend its use in standard practice, regional perfusion techniques could be considered as part
of a research protocol with research ethics board approval.
Oversight should include techniques to ensure the absence of
brain blood flow during regional perfusion.
Actionable Recommendation. “Should bronchoscopy versus no bronchoscopy be used for ante mortem evaluation of
lung function in potential pDCD donors?”
45) The panel did not make a recommendation for or against
the routine use of antemortem bronchoscopy in the setting of pDCD.
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Justification. Although bronchoscopy is frequently practiced
in neurologic determination of death and DCD organ donation, its association with graft or recipient outcome in pDCD
is not well described (75–77). We acknowledge that antemortem bronchoscopy prior to controlled pDCD is likely a low
risk procedure, but there are no published reports evaluating
adverse events rates in this setting. This balance of considerations led us to not recommend for or against antemortem
bronchoscopy.
The possibility of postmortem bronchoscopy either in situ
or ex vivo is unreported in the current literature but would
likely be of similar benefit as a pretransplant bronchoscopic
evaluation while eliminating risk conferred to the patient who
is a potential donor.
Cardiac pDCD
Good Practice Statements.
46) Considering the lack of published experience in cardiac
pDCD:
		

		

a) Cardiac transplant programs should establish criteria
for acceptance of heart donation, ex vivo cardiac protocols, and heart allocation in pDCD,
b) Consideration should be given to initiate cardiac pDCD
program as either research protocols with research ethics board oversight or through programs that oversee
innovative therapies.

Justification. Although there is minimal published experience with cardiac pDCD (78), recent innovative reports of
adult cardiac DCD using ex vivo heart preservation suggests
that this option may evolve as a viable clinical pathway in the
near future (79). We considered this lack of evidence when
recommending that future Canadian cardiac pDCD should be
undertaken under the supervision of a clinical trial or innovative therapy program.
Neonatal DCD
Good Practice Statements.
47) Unless otherwise stated, the above GPSs and actionable
recommendations that apply to infants and children
should also apply to neonates, provided expertise in neonatal EOL care can be provided.
48) Diagnoses such as anencephaly or other similar severe, lifelimiting neurologic disorders, for whom NDD is impossible, do not preclude consideration as potential candidates
for pDCD.
49) Centers not providing pDCD should establish a clear process for transfer to hospitals with pDCD programs including consideration of transfer of the mother of the patient
who is a potential donor, ongoing provision of EOL care,
limitation of economic burden on surrogate decision
makers, and repatriation of the body.
Justification. In general, we felt that there are more similarities than differences between neonatal and pediatric DCD
practice. As with all potential DCD donors, optimal EOL care
Pediatric Critical Care Medicine

should remain the fundamental concern in a neonatal pDCD
process. The particular relational and ethical aspects of neonatal death require the expertise of a clinician trained to deal
with these EOL issues (80, 81). Also, even less is known about
the rate of the dying process after WLST in neonates and how
that might affect completion of pDCD in this population,
which should be discussed with surrogates during the consent
process.
One of the potential differences between neonatal and other
populations is the relatively large numbers of regional, nontertiary NICUs that do not offer pDCD (compared with relatively
small number of PICUs) in which many potential neonatal
pDCD donors may be initially hospitalized. If parents of children hospitalized in NICUs that do not offer pDCD wish to
pursue pDCD, clear protocols for transfer would be necessary,
including consideration that the mother might not yet be eligible for transfer or discharge (82).
We recommend that pDCD can be offered to patients born
with anencephaly or other similar severe, life-limiting neurologic disorders. In 2016, the Canadian Paediatric Society reaffirmed its position statement (83) that recommends against
allowing deceased organ donation in this population based on
the impossibility to complete a NDD examination in the setting of a functional brain stem. This statement, however, was
based solely on NDD. Since pDCD is unaffected by the fact
that these patients do not fulfill NDD criteria, we recommend
that pDCD can be offered to the substitute decision makers of
patients born with this condition.
pDCD Implementation and Oversight
Good Practice Statements.
50) pDCD programs should seek out formal institutional
approval within the existing hospital reporting structure.
51) There should be an integrated, collaborative approach
to pDCD implementation with all hospital stakeholders,
family and/or public partners, regional ODOs, and transplant programs.
52) Local coroners should be contacted early in the process of
developing local pDCD procedures.
53) Communication and education of staff should be considered a priority during the development and implementation of a pDCD protocol.
54) pDCD case management review, including regular debriefing and a periodic quality assurance process, should occur.
55) Support for healthcare professionals involved in pDCD
should be provided.
Justification. The establishment of a pDCD program should
involve multidisciplinary collaboration with oversight from
appropriate local authorities. The need for communication and education of all involved stakeholders has also been
broadly emphasized in recent publications and was a frequently
expressed sentiment during our pDCD symposium (25, 81).
Quality control for this low-frequency, high-impact event is
critical for pDCD programs. This process should involve medical and ethical oversight, ideally with linkage to measures of
www.pccmjournal.org
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donor family experiences and transplant outcomes. Establishing robust ethical oversight also decreases the potential impact
of institutional bias toward organ donation. Organ donation
and transplantation activity are often a high-profile endeavor
within a healthcare system, and the positive exposure associated with these programs may lead to a perception that donation activity takes precedence over ethical safeguards. The
recognition and mitigation of this source of potential conflict
interest is an important aspect of maintaining professional and
public trust in the donation system.
Although we do not provide specific recommendation for
documentation, inherent in the quality assurance component
of recommendation 54 is the assumption that the process of
pDCD be well documented. We encourage teams developing
pDCD practices to visit the Canadian Blood Services website
link listed below to see sample clinical and administrative
checklists as well as documentation tools.

CONCLUSION
These recommendations are the result of a 3-year development process and represent the first pediatric-specific,
national guideline governing pDCD practice. The process was
transparent and based on the best available evidence that was
synthesized into recommendations using the most rigorous
methods possible. Review of this literature highlighted several
knowledge gaps that hopefully will be addressed by further
research in the field (5). For further information regarding our
methods and the justifications behind our recommendations,
please visit http://www.organsandtissues.ca/s/english-expert/
leading-practices-public-awareness-and-education for the full
report in English and French, as well as tools to facilitate pDCD
implementation. For questions regarding establishing a pDCD
program, please contact Dr. Weiss or Canadian Blood Services.
Although no guideline can perfectly address all concerns
held by all stakeholders, it is our sincere hope that application
of these guidelines can increase the number of organs available
to Canadians, while also offering the meaningful possibility of
organ donation to families experiencing the loss of a child.
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